Your browser doesn't support javascript.
loading
Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
Levin, Nancy; Spencer, Andrew; Harrison, Simon J; Chauhan, Dharminder; Burrows, Francis J; Anderson, Kenneth C; Reich, Steven D; Richardson, Paul G; Trikha, Mohit.
Affiliation
  • Levin N; Triphase Accelerator, San Diego, CA, USA.
  • Spencer A; Alfred Health, Monash University, Melbourne, Australia.
  • Harrison SJ; The Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Chauhan D; Dana Farber Cancer Institute, Boston, MA, USA.
  • Burrows FJ; Triphase Accelerator, San Diego, CA, USA.
  • Anderson KC; Dana Farber Cancer Institute, Boston, MA, USA.
  • Reich SD; Triphase Accelerator, San Diego, CA, USA.
  • Richardson PG; Dana Farber Cancer Institute, Boston, MA, USA.
  • Trikha M; Triphase Accelerator, San Diego, CA, USA.
Br J Haematol ; 174(5): 711-20, 2016 Sep.
Article in En | MEDLINE | ID: mdl-27161872
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrroles / Proteasome Endopeptidase Complex / Proteasome Inhibitors / Lactones / Multiple Myeloma Type of study: Clinical_trials Limits: Humans Language: En Journal: Br J Haematol Year: 2016 Type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrroles / Proteasome Endopeptidase Complex / Proteasome Inhibitors / Lactones / Multiple Myeloma Type of study: Clinical_trials Limits: Humans Language: En Journal: Br J Haematol Year: 2016 Type: Article Affiliation country: United States